WallStSmart

LivaNova PLC (LIVN)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 1663% more annual revenue ($25.27B vs $1.43B). SYK leads profitability with a 13.2% profit margin vs 7.5%. LIVN appears more attractively valued with a PEG of 0.91. SYK earns a higher WallStSmart Score of 59/100 (C).

LIVN

Buy

52

out of 100

Grade: C-

Growth: 5.3Profit: 5.5Value: 6.0Quality: 5.5
Piotroski: 4/9Altman Z: 0.35

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LIVNUndervalued (+6.1%)

Margin of Safety

+6.1%

Fair Value

$70.73

Current Price

$72.36

$1.63 discount

UndervaluedFair: $70.73Overvalued
SYKSignificantly Overvalued (-35.2%)

Margin of Safety

-35.2%

Fair Value

$223.02

Current Price

$305.66

$82.64 premium

UndervaluedFair: $223.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LIVN2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.918/10

Growing faster than its price suggests

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.44B9/10

Large-cap with strong market position

Areas to Watch

LIVN4 concerns · Avg: 2.3/10
Profit MarginProfitability
7.5%3/10

7.5% margin — thin

P/E RatioValuation
40.5x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-45.6%2/10

Earnings declined 45.6%

Altman Z-ScoreHealth
0.352/10

Distress zone — elevated risk

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
33.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : LIVN

The strongest argument for LIVN centers on Debt/Equity, PEG Ratio. Revenue growth of 14.3% demonstrates continued momentum. PEG of 0.91 suggests the stock is reasonably priced for its growth.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : LIVN

The primary concerns for LIVN are Profit Margin, P/E Ratio, EPS Growth. A P/E of 40.5x leaves little room for execution misses.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

LIVN carries more volatility with a beta of 0.88 — expect wider price swings.

LIVN is growing revenue faster at 14.3% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (59/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

LivaNova PLC

HEALTHCARE · MEDICAL DEVICES · USA

LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?